Awareness of newer prognostic factors might provide a potential direction for further improvement in treatment for EGFR-mutated non–small-cell lung cancer, especially adenocarcinoma, but no study has focused on hematologic and inflammatory markers in EGFR-mutant lung adenocarcinoma. This evidence concerns the gene EGFR and adenocarcinoma.